摘要
目的:分析乳腺癌复发患者原发灶和复发灶组织中激素受体(HR)、C-erbB-2及P-gp的表达差异及其临床意义。方法:免疫组化方法检测55例乳腺癌原发组织中ER、PR、C-erbB-2及P-gp的表达,并分析其变化情况。结果:原发灶组织中ER、C-erbB-2和P-gp的阳性表达分别为35/55、16/55、35/55,复发灶组织中ER、C-erbB-2和P-gp阳性表达分别为29/55、25/55和50/55,差异有统计学意义,P<0.05;原发灶和复发灶组织中PR表达差异无统计学意义,P>0.05。ER、PR、C-erbB-2和P-gp在原发灶和复发灶之间的变化率分别为54.5%、50.9%、30.9%和18.2%。结论:肿瘤原发灶与复发灶存在异质性,在对乳腺癌复发患者进行临床治疗时,应检测复发灶中分子表达的确切状况。
OBJECTIVE：To investigate the expression and clinical significance of ER,PR,C-erbB-2 and P-gp in primary breast cancer tissues and its recurrent focuses.METHODS： Immunohistochemistry assay was used to detect the expression and their changes of ER,PR,C-erbB-2 and P-gp in primary and recurrent focuses of 55 cases of breast cancer tissues.RESULTS： The expressions of ER、C-erbB-2 and P-gp in the primary breast cancer were 35/55,16/55,35/55 and 29/55,25/55,50/55 in the recurrent focuses,which were significantly different（P〈0.05）.The expression of PR was not significant（P〈0.05）.The changing rate of ER,PR,C-erbB-2 and P-gp was 54.5%,50.9%,30.9% and 18.2% respectively.CONCLUSION： The different molecular expression in the primary and recurrent focuses of breast cancer tissues should be detected in clinical practices.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第3期209-211,共3页
Chinese Journal of Cancer Prevention and Treatment
